CStone Pharmaceuticals

CStone Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines for cancer treatment. The company specializes in immuno-oncology therapies and has established a translational medicine research center in Suzhou, China.

Source: https://www.cstonepharma.com

sugemalimabCejemly

PD-L1 checkpoint inhibitor

Cejemly (sugemalimab) is a PD-L1 checkpoint inhibitor from CStone Pharmaceuticals approved in the European Union for non-small cell lung cancer. With platinum-based chemotherapy it is a first-line treatment of metastatic disease, and as monotherapy it treats unresectable stage III disease after chemoradiotherapy.

Sugemalimab is a fully human antibody given by infusion that binds PD-L1, a protein many cancer cells display to switch off attacking T cells. By bloc

1 medicine explained